Ongoing Phase 1 study to evaluate the safety and efficacy of investigational oral Cyclin A/B RxL Inhibitor CID-078 in patients with advanced solid tumor malignancies. The study will have approximately 100 participants and the duration for each participant is approximately three years.
National Trial Reference Number: NCT06577987
Sources for the below information are public registry websites such as ClinicalTrials.gov. It has been summarized and edited into simpler language. For full trial information about this clinical trial please visit https://clinicaltrials.gov.
The purpose of this study is to find the highest, safest dose of CID-078 that can be given to patients with advanced solid tumor malignancies and to evaluate the clinical activity of CID-078 in patients with selected solid tumor malignancies.
CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is designed to selectively target tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle’s cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple xenograft models.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
CID-078 is an investigational agent whose safety and efficacy in solid tumor malignancies has not been evaluated by the FDA or any other regulatory Agency.
Recruiting
>18 years
All
Advanced solid tumor malignancies including but not limited to breast and lung cancers.
View trial locations please visit https://clinicaltrials.gov
This site is intended for US residents only.
© 2024 Circle Pharma. All Rights Reserved.
Subscribe to our News Alerts